Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials

2014 ◽  
Vol 136 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Matteo Santoni ◽  
Alessandro Conti ◽  
Francesco Massari ◽  
Giorgio Arnaldi ◽  
Roberto Iacovelli ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Solid Tumors ◽  
Meta Analysis ◽  
Advanced Solid Tumors

scholarly journals Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

Oncotarget ◽  
2018 ◽  
Vol 9 (9) ◽  
pp. 8706-8715 ◽  
Author(s):  
Alberto Carretero-González ◽  
David Lora ◽  
Ismael Ghanem ◽  
Jon Zugazagoitia ◽  
Daniel Castellano ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Solid Tumors ◽  
Randomized Clinical Trials ◽  
Response Rate ◽  
Meta Analysis ◽  
Advanced Solid Tumors

Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21016-e21016
Author(s):  
Sonia Maria Seng ◽  
Ziyue Liu ◽  
Sophia Chiu ◽  
Tracey Proverbs-Singh ◽  
Guru Sonpavde ◽  
...  
Keyword(s):  
Relative Risk ◽  
Solid Tumors ◽  
Meta Analysis ◽  
Systemic Review ◽  
Advanced Solid Tumors ◽  
Thromboembolic Events ◽  
Patients With Cancer ◽  
Increased Risk ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

e21016 Background: Several reports suggest that cisplatin is associated with an increased risk of thromboembolism (TE). However, patients with solid tumors have multiple risk factors for TE and the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy as compared with non-cisplatin-based chemotherapy has not been well described. We performed a systemic review and meta-analysis of randomized controlled trials (RCTs) evaluating the incidence and risk of VTE associated with cisplatin-based chemotherapy. Methods: PubMed was searched for articles published from January 1, 1990 until December 31, 2010.The primary aim was to evaluate the association between treatment with cisplatin and VTEs in patients with cancer. Clinical trials that met the following criteria were included in the meta-analysis: (1) prospective randomized phase 2 and 3 trials of patients with cancer; (2) randomization to treatment with cisplatin versus a non-cisplatin containing chemotherapy regimen (3) available data on venous thromboembolic events. Data on all grade venous thromboembolic events was extracted. Study quality was calculated utilizing Jadad scores. Incidence rates, relative risks, and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses included the impact of publication year, tumor type, and cisplatin dose. Results: A total of 8216 patients with a variety of advanced solid tumors from 38 RCTs were included for analysis. Among patients treated with cisplatin-based chemotherapy, the summary incidence of VTE was 1.64% (95% CI, 1.06–2.25). Patients treated with cisplatin-based chemotherapy had a significantly increased risk of VTE with a relative risk of 1.65 (95% CI, 1.25–2.18; P = .01) compared with controls. Exploratory subgroup analysis revealed the highest relative risk of VTE in patients receiving a weekly equivalent cisplatin dose >30 mg/m2 (2.64; 95% CI, 1.18–5.77; P = .02) and in studies reported during 2000-2010 (1.70; 95% CI, 1.27–2.28; P = .01). Conclusions: Cisplatin chemotherapy is associated with a significant increase in the risk of VTE in patients with advanced solid tumors compared with non-cisplatin chemotherapy.

Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis

2017 ◽  
pp. 1-15 ◽  
Author(s):  
Monica Khunger ◽  
Adrian V. Hernandez ◽  
Vinay Pasupuleti ◽  
Sagar Rakshit ◽  
Nathan A. Pennell ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Solid Tumors ◽  
Immune Cell ◽  
Meta Analysis ◽  
Objective Response ◽  
Small Cell Lung ◽  
Programmed Cell Death 1 ◽  
Tumor Types

Purpose Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway show significant clinical activity across several tumor types. However, a majority of patients do not respond to these agents. Use of biomarker assays to predict response to these agents is an active area of research; however, the predictive value of PD-L1 immunohistochemistry (IHC) assays is largely inconsistent across clinical trials. In this meta-analysis of clinical trials of PD-1/PD-L1–targeted agents, we evaluate the predictive value of a tumor and tumor-infiltrating immune cell PD-L1 IHC assay as a biomarker for objective response to PD-1/PD-L1 inhibitors. Methods We searched databases (PubMed, Medline, ASCO abstracts, European Society for Medical Oncology abstracts, and Scopus) up until December 2016 for clinical trials using PD-1/PD-L1 inhibitors with reported PD-L1 biomarker data. Objective response rates (primary end point) from all phase I to III trials investigating nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab in advanced solid tumors were collected. Odds ratios (ORs) for response in PD-L1–positive patients compared with PD-L1–negative patients were calculated using the DerSimonian-Laird random effects model to combine trials. We performed meta-analysis as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results Forty-one distinct trials with 6,664 patients were identified. PD-L1 expression was predictive of favorable response across all tumor types (OR, 2.26; 95% CI, 1.85 to 2.75; P < .001), with the significantly largest effect observed in non–small-cell lung cancer (OR, 2.51; 95% CI, 1.99 to 3.17; P < .001). A subgroup analysis across all non–small-cell lung cancer trials using nivolumab and Dako clone 28-8 (Dako, Carpinteria, CA) IHC antibody assay yielded a significantly higher objective response rate in patients with tumor PD-L1 expression even at the minimum cutoff value of 1% (OR, 2.17; 95% CI, 1.03 to 4.57). Conclusion Our meta-analysis shows that tumor and tumor-infiltrating immune cell PD-L1 overexpression based on IHC is associated with significantly higher response rates to PD-1/PD-L1 axis inhibitors across a range of malignant solid tumors.

scholarly journals Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials

Oncotarget ◽  
2019 ◽  
Vol 10 (35) ◽  
pp. 3294-3301 ◽  
Author(s):  
Alberto Carretero-González ◽  
David Lora ◽  
Ismael Ghanem ◽  
Irene Otero ◽  
Flora López ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Solid Tumors ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Safety Analysis ◽  
Comparative Safety

Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3064-3064 ◽  
Author(s):  
Ricardo Lima Barros Costa ◽  
Benedito A. Carneiro ◽  
Alfred Rademaker ◽  
Mark Agulnik ◽  
Victoria Meucci Villaflor ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Solid Tumors ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Toxicity Profile
Sign in / Sign up

Export Citation Format

Share Document